Finerenone: trayectory from the evidence to standard use en patients with diabetes and renal disease

Authors

  • Daniela García Brasca Instituto de Cardiología Hospital Italiano de Córdoba - Facultad de Ciencias Médicas, Universidad Nacional de Córdoba. Argentina
  • Sergio Gimenez Servicio de Cardiología O.S.E.P., Mendoza, Argentina
  • Nicolás Renna Hospital Español de Mendoza. Facultad de Ciencias Médicas, Universidad Nacional de Cuyo-CONICET. Mendoza, Argentina
  • Marcelo Orias Yale University, New Haven, Connecticut, USA

Keywords:

Finerenone, Diabetes, Renal disease

Abstract

  • DIABETES AND KIDNEY DISEASE: EPIDEMIOLOGY AND PERSPECTIVE
  • IMPACT OF MINERALOCORTICOID RECEPTORS IN THE PATHOPHYSIOLOGY OF KIDNEY DISEASE PROGRESSION
  • CARDIOVASCULAR IMPACT OF DIABETIC KIDNEY DISEASE
  • FINERENONE IN DIABETIC KIDNEY DISEASE: THE PATH OF EVIDENCE
  • RENAL AND CARDIOVASCULAR OUTCOMES
  • COMPREHENSIVE APPROACH TO THE PATIENT WITH KIDNEY DISEASE
  • CURRENT RECOMMENDATIONS IN NATIONAL AND INTERNATIONAL GUIDELINES

Downloads

Published

2023-07-31

Issue

Vol. 52 (2023): Supplement: Mineralocorticoid antagonists in the cardio-renal-metabolic continuum: emerging role of finerenone

Section

Review Article

How to Cite

1.
Finerenone: trayectory from the evidence to standard use en patients with diabetes and renal disease. Rev. Fed. Arg. Cardiol. [Internet]. 2023 Jul. 31 [cited 2024 May 17];52:15-20. Available from: https://revistafac.org.ar/ojs/index.php/revistafac/article/view/509